MARKET NEWS

Beta Bionics Receives FDA Breakthrough Device Designation
Inceptua Medicines Access & Onconova Therapeutics Announce Pre-Approval Access Collaboration
Fate Therapeutics Presents its First Off-the-Shelf, iPSC-Derived CAR T-Cell Immunotherapy Program
Retrogenix & Resonant Therapeutics Announce Strategic Alliance
Navigen Announces FDA Clearance of its IND Application
Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration With MSD

  FEATURED EDITORIAL

  COMPANY PROFILE

Credence MedSystems is setting a new standard in drug delivery, helping you differentiate your products through innovative delivery systems while preserving your trusted processes. Simple, safe, and intuitive usability creates a better, safer experience for patients and healthcare professionals. Innovative designs provide safety activation clicks, end-of-dose feedback cues, and automatic needle retraction—without changes to familiar injection procedures. Our unique product innovations coexist with your existing processes, avoiding disruption to your filling lines and simplifying your secondary packaging operations. Use the primary container and components of your choice. Maintain your preferred sourcing strategy and manufacturing processes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

HIGH PURITY EXCIPIENTS - A Simple Solution to a Complex Problem

William Small, PhD, and Arsalan Khan say drug degradation can have toxicological effects in many instances, and it is imperative that this mechanism be minimized as much as possible. The best solution to this is to ensure that appropriate ingredients, both high in quality and purity, are chosen and used throughout the entire drug product lifecycle.

Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug

Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug

Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….

Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment

Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment

Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….

Diagnosed Prevalent Cases of Chronic Heart Failure to Reach 32 Million

Diagnosed Prevalent Cases of Chronic Heart Failure to Reach 32 Million

Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM) occur in the elderly population, and this is estimated to increase by a further….

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study

Tonix Pharmaceuticals Holding Corp. recently announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304)……

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 8 – Capsules
January 15 – Excipients